Seperidol

Seperidol

SCHEMBL124937

O=C(CCCN1CCC(O)(c2ccc(Cl)c(C(F)(F)F)c2)CC1)c1ccc(F)cc1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 16/20 0.80
HTR1A P08908 7/20 0.72
DRD4 P21917 7/20 0.72
HTR2A P28223 7/20 0.72
HTR2C P28335 7/20 0.72
HTR7 P34969 7/20 0.72
OPRM1 P35372 7/20 0.72
HRH2 P25021 6/20 0.72
DRD3 P35462 6/20 0.72
HTR2B P41595 6/20 0.72
OPRK1 P41145 6/20 0.72
HRH1 P35367 5/20 0.72
DRD1 P21728 5/20 0.71
DRD5 P21918 5/20 0.71
SLC6A2 P23975 5/20 0.71
SLC6A4 P31645 5/20 0.71
HTR6 P50406 5/20 0.71
SLC6A3 Q01959 5/20 0.71
HTR5A P47898 4/20 0.71
ABCB11 O95342 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Seperidol SCHEMBL124936 0.99 DRD2 (0.78) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11382049 0.88 DRD2 (0.62) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11858251 0.88 DRD2 (0.74) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11463963 0.87 DRD2 (0.62) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11609688 0.86 DRD2 (0.61) DRD2HTR1ADRD4HTR2AHTR2C
Hydrochloric Acid SCHEMBL11469274 0.86 DRD2 (0.61) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL14282239 0.84 OPRM1 (0.76) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL9054984 0.84 DRD2 (1.00) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11846146 0.84 DRD2 (0.61) DRD2HTR1ADRD4HTR2AHTR2C
SCHEMBL11715692 0.83 OPRM1 (0.65) DRD2HTR1ADRD4HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 US claimed
US-20100234288-A1 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A pH-DEPENDENT POLYMER PANACEA BIOTEC LTD (IN) 2010-09-16 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
US-20090220611-A1 Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same FLAMEL TECHNOLOGIES, S.A. (FR) 2009-09-03 US claimed
EP-2004150-A1 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION ON THE BASIS OF A RELEASE SYSTEM COMPRISING AN ACID-SOLUBLE POLYMER AND A PH-DEPENDENT POLYMER. Panacea Biotec Ltd. (IN) 2008-12-24 EP claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007036671-A2 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME FLAMEL TECHNOLOGIES (FR) 2007-04-05 WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
EP-1044023-B1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA LUITPOLD PHARM INC (US) 2005-05-25 EP claimed
US-6197764-B1 COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS PROTARGA, INC. 2001-03-06 US claimed
EP-1044023-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA Protarga Inc. (US) 2000-10-18 EP claimed
US-5955459-A Fatty acid-antipsychotic compositions and uses thereof NEUROMEDICA, INC. (US) 1999-09-21 US claimed
WO-1999026661-A1 A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA PROTARGA INC. (US) 1999-06-03 WO claimed
US-4565821-A 4-PIPERADINO-4*-FLUOROBUTYROPHENONES THE TEXAS A&M UNIVERSITY SYSTEM (US) 1986-01-21 US claimed